Compare · DFTX vs PRDS
DFTX vs PRDS
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Pardes Biosciences Inc. (PRDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and PRDS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.56B, about 6.9x PRDS ($657.5M).
- DFTX has hit the wire 8 times in the past 4 weeks while PRDS has been quiet.
- DFTX has more recent analyst coverage (6 ratings vs 3 for PRDS).
- Company
- Definium Therapeutics Inc.
- Pardes Biosciences Inc.
- Price
- $41.77-3.99%
- $2.19+1.39%
- Market cap
- $4.56B
- $657.5M
- 1M return
- -5.55%
- -
- 1Y return
- +345.97%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 6
- 3
PRDS
Pardes Biosciences Inc.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
- Wells Fargo initiated coverage on Definium Therapeutics with a new price target
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Latest PRDS
- SEC Form 15-12G filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares
- SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)
- SEC Form 4: Wiggans Thomas G closing all direct ownership in the company
- SEC Form 4: Varney Michael David closing all direct ownership in the company
- SEC Form 4 filed by Smaldone Alsup Laurie
- SEC Form 4 filed by Pottage John C Jr
- SEC Form 4: Lopatin Uri A closing all direct ownership in the company